Literature DB >> 33555780

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update.

Waleed Alhazzani1,2, Laura Evans3, Fayez Alshamsi4, Morten Hylander Møller5,6, Marlies Ostermann7, Hallie C Prescott8, Yaseen M Arabi9, Mark Loeb1,2, Michelle Ng Gong10, Eddy Fan11, Simon Oczkowski1,2, Mitchell M Levy12,13, Lennie Derde14,15, Amy Dzierba16, Bin Du17, Flavia Machado18, Hannah Wunsch19,20, Mark Crowther1,2, Maurizio Cecconi21,22, Younsuck Koh23, Lisa Burry24, Daniel S Chertow25, Wojciech Szczeklik26, Emilie Belley-Cote1,27, Massimiliano Greco21,22, Malgorzata Bala28, Ryan Zarychanski29, Jozef Kesecioglu14, Allison McGeer30, Leonard Mermel12, Manoj J Mammen31, Sheila Nainan Myatra32, Amy Arrington33, Ruth Kleinpell34, Giuseppe Citerio35,36, Kimberley Lewis1,2, Elizabeth Bridges37, Ziad A Memish38, Naomi Hammond39,40, Frederick G Hayden41, Muhammed Alshahrani42, Zainab Al Duhailib2,43, Greg S Martin44, Lewis J Kaplan45, Craig M Coopersmith46, Massimo Antonelli47,48, Andrew Rhodes49.   

Abstract

BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions worldwide. Given the rapidly growing evidence base, we implemented a living guideline model to provide guidance on the management of patients with severe or critical coronavirus disease 2019 in the ICU.
METHODS: The Surviving Sepsis Campaign Coronavirus Disease 2019 panel has expanded to include 43 experts from 14 countries; all panel members completed an electronic conflict-of-interest disclosure form. In this update, the panel addressed nine questions relevant to managing severe or critical coronavirus disease 2019 in the ICU. We used the World Health Organization's definition of severe and critical coronavirus disease 2019. The systematic reviews team searched the literature for relevant evidence, aiming to identify systematic reviews and clinical trials. When appropriate, we performed a random-effects meta-analysis to summarize treatment effects. We assessed the quality of the evidence using the Grading of Recommendations, Assessment, Development, and Evaluation approach, then used the evidence-to-decision framework to generate recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility.
RESULTS: The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued nine statements (three new and six updated) related to ICU patients with severe or critical coronavirus disease 2019. For severe or critical coronavirus disease 2019, the panel strongly recommends using systemic corticosteroids and venous thromboprophylaxis but strongly recommends against using hydroxychloroquine. In addition, the panel suggests using dexamethasone (compared with other corticosteroids) and suggests against using convalescent plasma and therapeutic anticoagulation outside clinical trials. The Surviving Sepsis Campaign Coronavirus Diease 2019 panel suggests using remdesivir in nonventilated patients with severe coronavirus disease 2019 and suggests against starting remdesivir in patients with critical coronavirus disease 2019 outside clinical trials. Because of insufficient evidence, the panel did not issue a recommendation on the use of awake prone positioning.
CONCLUSION: The Surviving Sepsis Campaign Coronavirus Diease 2019 panel issued several recommendations to guide healthcare professionals caring for adults with critical or severe coronavirus disease 2019 in the ICU. Based on a living guideline model the recommendations will be updated as new evidence becomes available.
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33555780     DOI: 10.1097/CCM.0000000000004899

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  95 in total

1.  Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.

Authors:  João João Mendes; José Artur Paiva; Filipe Gonzalez; Paulo Mergulhão; Filipe Froes; Roberto Roncon; João Gouveia
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24

Review 2.  2020 Year in Review: Pharmacologic Treatments for COVID-19.

Authors:  Jessica L Saunders; Michael D Davis
Journal:  Respir Care       Date:  2021-04-12       Impact factor: 2.258

3.  High-flow Nasal Cannula therapy: A feasible treatment for vulnerable elderly COVID-19 patients in the wards.

Authors:  Job van Steenkiste; Michael C van Herwerden; Dolf Weller; Christiaan J van den Bout; Rikje Ruiter; Jan G den Hollander; Rachida El Moussaoui; Gert T Verhoeven; Charlotte van Noord; Marinus A van den Dorpel
Journal:  Heart Lung       Date:  2021-05-25       Impact factor: 2.210

Review 4.  Diagnosis and management of acute respiratory distress syndrome.

Authors:  Shannon M Fernando; Bruno L Ferreyro; Martin Urner; Laveena Munshi; Eddy Fan
Journal:  CMAJ       Date:  2021-05-25       Impact factor: 8.262

5.  Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium.

Authors:  Bernard Lambermont; Anne-Françoise Rousseau; Laurence Seidel; Marie Thys; Jonathan Cavalleri; Pierre Delanaye; J Geoffrey Chase; Pierre Gillet; Benoit Misset
Journal:  Crit Care Explor       Date:  2021-05-19

Review 6. 

Authors:  Shannon M Fernando; Bruno L Ferreyro; Martin Urner; Laveena Munshi; Eddy Fan
Journal:  CMAJ       Date:  2021-06-21       Impact factor: 8.262

7.  Post-infectious and post-acute sequelae of critically ill adults with COVID-19.

Authors:  Halah Ibrahim; Syed Athar; Thana Harhara; Shahad Abasaeed Elhag; Salma MElnour; Hoor H Sukkar; Ashraf M Kamour
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

Review 8.  The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome.

Authors:  Denise Battaglini; Chiara Robba; Andrea Fedele; Sebastian Trancǎ; Samir Giuseppe Sukkar; Vincenzo Di Pilato; Matteo Bassetti; Daniele Roberto Giacobbe; Antonio Vena; Nicolò Patroniti; Lorenzo Ball; Iole Brunetti; Antoni Torres Martí; Patricia Rieken Macedo Rocco; Paolo Pelosi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

Review 9.  Respiratory care for the critical patients with 2019 novel coronavirus.

Authors:  Yao-Chen Wang; Min-Chi Lu; Shun-Fa Yang; Mauo-Ying Bien; Yi-Fang Chen; Yia-Ting Li
Journal:  Respir Med       Date:  2021-06-21       Impact factor: 3.415

10.  Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study.

Authors:  Ali Rezaie; Gil Y Melmed; Gabriela Leite; Ruchi Mathur; Will Takakura; Isabel Pedraza; Michael Lewis; Rekha Murthy; George Chaux; Mark Pimentel
Journal:  Adv Ther       Date:  2021-06-26       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.